NCT07520006 2026-04-13
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Not yet recruiting
Clinical Trials
22 trialsNCT07503353 2026-03-31
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Sheba Medical Center
Phase 1/2 Not yet recruiting
NCT07486726 2026-03-20
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Not yet recruiting
NCT07372885 2026-03-11
GRACE
University of Manchester
Phase 1/2 Not yet recruiting
NCT07053020 2026-03-04
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT07370064 2026-01-27
AML CAR-T
Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT07311746 2025-12-31
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07026942 2025-11-12
CD33 CAR NK
Nationwide Children's Hospital
Phase 1/2 Not yet recruiting
NCT06979076 2025-09-29
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
MingSight Pharmaceuticals, Inc
Phase 1/2 Not yet recruiting
NCT06281847 2025-09-18
RESOLVE AML001
Advesya SAS
Phase 1/2 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT07084584 2025-07-24
An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Galecto Biotech AB
Phase 1/2 Not yet recruiting
NCT07020260 2025-06-13
PACMAN
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT06684509 2024-11-12
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
Assiut University
Phase 1/2 Not yet recruiting
NCT06387420 2024-04-29
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Akeso
Phase 1/2 Not yet recruiting
NCT05319249 2024-04-05
NAKIP-AML
German Cancer Research Center
Phase 1/2 Not yet recruiting
NCT06333509 2024-03-27
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06180499 2024-02-14
ILDTreg2
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Not yet recruiting
NCT05055791 2021-09-24
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05054465 2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2 Not yet recruiting